News

Diving for novel antibiotics
Enlarge image

ResearchEUBelgiumUK

Diving for novel antibiotics

15.02.2013 - The EU-project PharmaSea will bring researchers to some of the deepest, coldest and hottest places on the planet in the hunt for novel antibiotics.

Scientists from the UK, Belgium, Norway, Spain, Ireland, Germany, Italy, Switzerland and Denmark will work together to collect and screen samples of mud and sediment from huge, previously untapped, oceanic trenches. The large-scale, four-year project is backed by more than €9.5 million of EU funding and brings together 24 partners from 14 countries from industry, academia and non-profit organisations.

The PharmaSea project focuses on biodiscovery research and the development and commercialisation of new bioactive compounds from marine organisms, including deep-sea sponges and bacteria, to evaluate their potential as novel drug leads or ingredients for nutrition or cosmetic applications. The international team of scientists is led by Professor Marcel Jaspars of the University of Aberdeen in Scotland, and coordinated by Dr. Camila Esguerra of the University of Leuven in Belgium.

Only a handful of samples have ever been taken from deep trenches and investigated, so the project is breaking new ground. "PharmaSea will not only be exploring new territory at the bottom of the oceans, but also new areas in ‘chemical space’. With our broad platform of cutting-edge bioassays to detect drug-like activity, we'll be testing many unique chemical compounds from these marine samples that have literally never seen the light of day. We're quite hopeful that we'll find a number of exciting new drug leads", says Dr. Camila Esguerra, Industrial Research Fellow and Lecturer with the Laboratory for Molecular Biodiscovery at the University of Leuven.

The international team will employ strategies commonly used in the salvage industry to carry out the sampling. Using fishing vessels, researchers will drop a sampler on a reel of cables to the trench bed to collect sediment. Scientists will then attempt to grow unique bacteria and fungi from the sediment that can be extracted to isolate novel drug-like molecules for pharmacological testing. Partners from China, Chile, Costa Rica, New Zealand and South Africa will support the PharmaSea project. The first field tests will be carried out next autumn in the Atacama Trench in the Eastern Pacific Ocean, about 100 miles off the coast of Chile and Peru. The team will also search the Arctic waters off Norway and the Antarctic via Italian and South African partners. Deep trenches will also be accessed off New Zealand and China.

Marine organisms that live more than 6,000 meters below the sea level are considered to be an interesting source of novel bioactive compounds as they survive under extreme conditions. "Trenches are separated from each other and represent islands of diversity. They are not connected to each other and life has evolved differently in each one", explains Marcel Jaspars. 

© eurobiotechnews.eu/al

http://www.european-biotechnology-news.com/news/news/2013-01/plunging-new-depths-for-novel-antibiotics.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)24.00 NOK23.71%
  • TRANSGENE (F)4.72 EUR23.56%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%

FLOP

  • THROMBOGENICS (B)3.09 EUR-20.97%
  • ZELTIA (E)3.35 EUR-12.76%
  • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%

TOP

  • KARO BIO (S)38.50 SEK2336.7%
  • TRANSGENE (F)4.72 EUR65.6%
  • BIOTECH PHARMACON (N)12.50 NOK32.0%

FLOP

  • THROMBOGENICS (B)3.09 EUR-39.3%
  • BIONOR PHARMA (N)1.26 NOK-38.2%
  • WILEX (D)2.05 EUR-37.5%

TOP

  • KARO BIO (S)38.50 SEK4595.1%
  • ADOCIA (F)87.65 EUR438.1%
  • GALAPAGOS (B)54.02 EUR329.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.84 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.7%

No liability assumed, Date: 28.08.2015